Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer

NCT04222972 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT04222972
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04222972 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Terminated
Start date
July 24, 2020
Completion date
January 27, 2025
Enrollment
223 (actual)
Sites
74

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma, bronchial diseases, carcinoma, carcinoma, bronchogenic, carcinoma, non-small-cell lung, head and neck neoplasms, lung diseases, lung neoplasm, neoplasms, neoplasms by histologic type, neoplasms by site, neoplasms, germ cell and embryonal, neoplasms, nerve tissue, respiratory tract disease, respiratory tract neoplasms, ret-fusion non small cell lung cancer, thoracic neoplasms